Novartis

News

Boy in wheelchair, only lower half of his body visible

Novartis' SMA gene therapy cleared for wider use in US

A new FDA approval means Novartis now has a gene therapy option for almost everyone with spinal muscular atrophy (SMA), regardless of their age.

News

Novartis says novel drug could counter malaria resistance

Novartis has reported what looks like another big step forward in the treatment of malaria, as a drug with a novel mechanism hits the mark in phase 3.

News

Novartis' new drugs outweigh Entresto decline in Q3

Now feeling the impact of generic competition on its top product Entresto in the US, Novartis is still looking for pipeline-building deals, says CEO.

News

Novartis makes $12bn wager on RNA drugs with Avidity buy

Novartis is poised to make one of its largest takeover deals in its history after agreeing to buy RNA specialist Avidity Biosciences for $12bn.

News

ESMO: Lilly reveals scale of survival win with Verzenio

Eli Lilly has revealed long-term follow-up data with adjuvant Verzenio in early breast cancer, including a 15.8% improvement in survival.

News

Sanofi, Orano cue up filings for GEP-NET radioligand therapy

Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.

Novartis' SMA gene therapy cleared for wider use in US

Novartis says novel drug could counter malaria resistance

Novartis' new drugs outweigh Entresto decline in Q3

Novartis makes $12bn wager on RNA drugs with Avidity buy

ESMO: Lilly reveals scale of survival win with Verzenio

Sanofi, Orano cue up filings for GEP-NET radioligand therapy

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Novartis

Editor's Picks